Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

DIPENTUM 250 MG CAPSULE

olsalazine sodium
$15.6962per EA

Strength

250 mg/1

Manufacturer

Viatris Specialty LLC

NDC

00037686010

Classification

Brand

Dosage Form

CAPSULE, GELATIN COATED

Route

ORAL

Last Updated

1/1/2026

Active Ingredients

OLSALAZINE SODIUM

Approval Type

New Drug (NDA)

FDA Application

NDA019715

On Market Since

5/15/2015

Pharmacological Classes

Aminosalicylate
Aminosalicylic Acids

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

+5.0%

1Y

+5.0%

3Y

+28.1%

5Y

+28.1%

All

+46.4%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

PENTASA 250 MG CAPSULE
Brand
54092018981•Takeda Pharmaceuticals America, Inc.
$2.9049
per EA
APRISO ER 0.375 GRAM CAPSULE
Brand
65649010302•Salix Pharmaceuticals Inc.
$4.0710
per EA
PENTASA 500 MG CAPSULE
Brand
54092019112•Takeda Pharmaceuticals America, Inc.
$5.8207
per EA
LIALDA DR 1.2 GM TABLET
Brand
54092047601•Takeda Pharmaceuticals America, Inc.
$8.9473
per EA
LIALDA DR 1.2 GM TABLET
Brand
54092047602•Takeda Pharmaceuticals America, Inc.
$8.9473
per EA
LIALDA DR 1.2 GM TABLET
Brand
54092047612•Takeda Pharmaceuticals America, Inc.
$8.9473
per EA
CANASA 1,000 MG SUPPOSITORY
Brand
58914050156•Allergan, Inc.
$37.0791
per EA
CANASA 1,000 MG SUPPOSITORY
Brand
58914050142•Allergan, Inc.
$37.0918
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy